Member
View entire report under Key Issues.
Headlines
The Food and Drug Administration Nov. 10 issued an emergency use authorization (EUA) for Eli Lilly and Company’s monoclonal antibody therapy, bamlanivimab. The EUA authorizes the product’s use, but only in outpatient settings; additionally, it sets forth the type of patients eligible to receive the…
In anticipation of the likely issuance of emergency use authorizations (EUAs) for at least two monoclonal antibody therapeutic drugs developed to treat certain COVID-19 positive patients, Operation Warp Speed released an initial playbook to assist providers in planning. The playbook lays out…
Dr. Estes is joined by Kevin W. Sowers, President of the Johns Hopkins Health System and Executive Vice President of Johns Hopkins Medicine, to discuss how hospitals can move from relief, recovery, and rebuilding to reimagining and innovation.
The AHA Nov. 10, at 2 p.m. ET will host an all-member live virtual advocacy event.
The Centers for Medicare & Medicaid Services’ hospital price transparency final rule is effective Jan. 1, 2021. This rule, among other things, requires hospitals to disclose their privately negotiated rates with health insurers, discounted cash prices and gross charges.
The Centers for Medicare & Medicaid Services’ hospital price transparency final rule is effective Jan. 1, 2021. This rule, among other things, requires hospitals to disclose their privately negotiated rates with health insurers, discounted cash prices and gross charges.
The AHA on Friday sent a letter to the Health Resources and Services Administration’s Office of Pharmacy Affairs urging the agency to order drug manufacturers and their vendor Kalderos to immediately halt their conversion of the 340B program to a back-end rebate program.
The Department of Health and Human Services issued an important clarification to its Oct. 22 reporting requirements for providers that received Provider Relief Fund payments.